#ESMO26: The potent KRAS G12C inhibitor divarasib outperforms sotorasib and adagrasib in advanced KRAS G12C-mutated non-small cell lung cancer (#NSCLC) in the phase III Krascendo 1

ESMO - Eur. Oncology· @myESMO · X·2026-10-25 23:35· 1 天前评分70

正文 · 原文

#ESMO26: The potent KRAS G12C inhibitor divarasib outperforms sotorasib and adagrasib in advanced KRAS G12C-mutated non-small cell lung cancer (#NSCLC) in the phase III Krascendo 1 #ClinicalTrial.

Read more
🔗 https://ow.ly/fm3250ZZG4k

#InsightsbyESMO #LungCancer

115 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

来源：ESMO - Eur. Oncology · x.com